European Molecular Biology Organization

bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post

Retrieved on: 
Tuesday, November 28, 2023
Research, Medical Devices, Surgery, Genetics, Biotechnology, Radiology, Pharmaceutical, Health, Science, Oncology, BIAF, ASCB, Cell biology, Student, Cell, European, EMBO, European Molecular Biology Organization, Society, Government, Education, Pharmaceutical industry, Management

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced that David Elzi, Ph.D., bioAffinity Technologies Vice President of Research, has been named to the Membership Committee of the American Society for Cell Biology (ASCB).

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced that David Elzi, Ph.D., bioAffinity Technologies Vice President of Research, has been named to the Membership Committee of the American Society for Cell Biology (ASCB).
  • First organized in 1960, ASCB is an international organization of cell biologists dedicated to advancing scientific discovery, advocating sound research policies, improving education, promoting professional development and increasing diversity in the scientific workforce.
  • The Membership Committee is responsible for implementing programs and services to meet the needs of the ASCB’s membership and support its mission and strategic plan, including recruiting new members and retaining current members.
  • Aimed at students, post-docs and research scientists, the roundtable will be held Dec. 3, 2023, at 1:15 p.m.

The Dreyfus Prize in the Chemical Sciences Winner Announced

Retrieved on: 
Friday, May 12, 2023
Research, Biotechnology, Other Education, Radiology, Collegiate, Consumer, Health, Science, Education, Other Science, Dreyfus Prize in the Chemical Sciences, Neuron, National academy, University of Chicago, Chemistry, Pritzker School, University of the Chinese Academy of Sciences, Harvard University, European Molecular Biology Organization, Breakthrough Prize in Life Sciences, Dean, Howard Hughes Medical Institute, American Academy, The Camille and Henry Dreyfus Foundation, Biomedical sciences, Multimedia, Brain, Cell, RNA, MacArthur Fellows Program, Biochemistry, Neuroscience, Chemical substance, Vilcek Foundation, National Academy of Medicine, European, University, Heineken Prizes, National Academy of Inventors, Biology, Pearl Meister Greengard Prize, L'Oréal-UNESCO For Women in Science Awards, American Philosophical Society, Genome, Breakthrough Prize, Pharmaceutical industry, Microscope, Medicine, Imaging, Biophysics

Professor of Science, Harvard University, is the recipient of the 2023 Dreyfus Prize in the Chemical Sciences.

Key Points: 
  • Professor of Science, Harvard University, is the recipient of the 2023 Dreyfus Prize in the Chemical Sciences.
  • The international biennial Prize, which includes a $250,000 award, is conferred this year in Imaging in the Chemical Sciences.
  • View the full release here: https://www.businesswire.com/news/home/20230511005909/en/
    Xiaowei Zhuang of Harvard University announced as recipient of the 2023 Dreyfus Prize in the Chemical Sciences (Photo: Business Wire)
    Zhuang receives this top honor for her pivotal contributions to Imaging in the Chemical Sciences.
  • I would like to thank the Camille and Henry Dreyfus Foundation for being a leading supporter of the chemical sciences community for over 75 years.”
    The Dreyfus Prize in the Chemical Sciences, initiated in 2009, is conferred in a specific area of chemistry each cycle.

EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update

Retrieved on: 
Tuesday, April 25, 2023
Vaccine, Operating cost, GSK, GMP, Omicron, CureVac COVID-19 vaccine, Civil service commission, European Molecular Biology Organization, COVID-19, Infection, Clinical trial, CureVac, Cancer, BMBF, PEG, CMOS, Temperature, CMO, Element, Federal Ministry of Health (Germany), Messenger, Trial of the century, Boehringer Ingelheim, EMBO, Patient, European, Melanoma, Epitope, Webcast, LNP, PD-1, CVAC, Therapy, WHO, EC, Virus, Education, European Commission, Safety, Fatigue, Cryptocurrency, Fine chemical, Pharmaceutical industry, Research

All candidates are based on CureVac’s proprietary second-generation mRNA backbone, targeting improved intracellular mRNA translation for early and strong immune responses.

Key Points: 
  • All candidates are based on CureVac’s proprietary second-generation mRNA backbone, targeting improved intracellular mRNA translation for early and strong immune responses.
  • On January 6 and January 30, 2023, CureVac announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and flu.
  • As of December 31, 2022, CureVac has settled most of its financial obligations related to CVnCoV.
  • In the first quarter of 2022, CureVac received a €10 million milestone payment related to the initiation of the seasonal flu clinical trial.

Carcell welcomes Prof. Harvey Lodish as Chair of its Scientific Advisory Board

Retrieved on: 
Monday, December 19, 2022
Sanofi, Nobel Prize, European, Coronavirus Scientific Advisory Board (Turkey), Cell, Assistant, RBC, Whitehead Institute, Chemistry, Degenerative disease, National academy, National university, Student, American Association for Cancer Research, Takeda, Reticulocyte, Investment, MIT, Physiology, Stem cell, Cancer, Brown University, Genzyme, European Molecular Biology Organization, Knowledge, Multimedia, Massachusetts Institute of Technology, Biological engineering, Cell biology, American Academy, National University of Singapore, National Center for Advancing Translational Sciences, Research, Biomedical Research, Red blood cell, Takeda Oncology, Patient, Therapy, Medical device, Pharmaceutical industry, Science, Biology, Medicine, Yves Carcelle

SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.

Key Points: 
  • SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.
  • He joins Prof. Jianzhu Chen of the Massachusetts Institute of Technology (MIT) and Dr. Hagop Youssoufian of Brown University on Carcell's Scientific Advisory Board to propel scientific advancement of its cell and gene therapy platforms.
  • Prof. Lodish brings onboard decades of experience in biotech and especially red blood cell (RBC)-based therapeutics to the team.
  • XQ Lin, the Chairman of Carcell, commented, "We are delighted to have Prof. Lodish join us as the Chair of our Scientific Advisory Board.

Carcell welcomes Prof. Harvey Lodish as Chair of its Scientific Advisory Board

Retrieved on: 
Monday, December 19, 2022
Sanofi, Nobel Prize, European, Coronavirus Scientific Advisory Board (Turkey), Cell, Assistant, RBC, Whitehead Institute, Chemistry, Degenerative disease, National academy, National university, Student, American Association for Cancer Research, Takeda, Reticulocyte, Investment, MIT, Physiology, Stem cell, Cancer, Brown University, Genzyme, European Molecular Biology Organization, Knowledge, Massachusetts Institute of Technology, Biological engineering, Cell biology, American Academy, National University of Singapore, National Center for Advancing Translational Sciences, Research, Biomedical Research, Red blood cell, Takeda Oncology, Patient, Therapy, Medical device, Pharmaceutical industry, Science, Biology, Medicine, Yves Carcelle

SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.

Key Points: 
  • SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.
  • He joins Prof. Jianzhu Chen of the Massachusetts Institute of Technology (MIT) and Dr. Hagop Youssoufian of Brown University on Carcell's Scientific Advisory Board to propel scientific advancement of its cell and gene therapy platforms.
  • Prof. Lodish brings onboard decades of experience in biotech and especially red blood cell (RBC)-based therapeutics to the team.
  • XQ Lin, the Chairman of Carcell, commented, "We are delighted to have Prof. Lodish join us as the Chair of our Scientific Advisory Board.

Newtown's Apple to Highly Saturated Global Molecular Market, TIANGEN TGuide S16 Automated Nucleic Acid Extractor Showcased at Cell Bio 2022

Retrieved on: 
Tuesday, December 6, 2022
Duke University, Cell biology, Thomas D. Pollard, Society, Research, ASCB, Cell, S16, University of California, Molecular biology, Wizard Product Review, EMBO, University, GM, European Molecular Biology Organization, Harvard Medical School, RNA, Fine chemical, A4

Eye-catching as it is, the smart automated extractor hit the great potential need of global research scientists about nucleic acid purification and received more than 50 direct trial requests.

Key Points: 
  • Eye-catching as it is, the smart automated extractor hit the great potential need of global research scientists about nucleic acid purification and received more than 50 direct trial requests.
  • For molecular and cell biologists, nucleic acid purification column kits are highly redundant in the global molecular market.
  • Serving these demands, TIANGEN designed the groundbreaking research oriented automated extractor: the TGuide S16, empowered by insights of scientist behaviors and expectations, the 12-year experience on automated extractors, and rich supporting reagent kit pools.
  • It has been committed to providing customers with a total solution from sample storage to nucleic acid extraction and detection.

bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

Retrieved on: 
Thursday, December 1, 2022
Research, Surgery, Medical Devices, Genetics, Biotechnology, Radiology, Health, Science, Oncology, Marketing, EST, Thomas D. Pollard, European Molecular Biology Organization, Laboratory, Lung, Gene, CD320, Brain, ASCB, University of Texas Southwestern Medical Center, University, Cell biology, Prostate, Society, Laboratory developed test, Sirna Therapeutics, LDT, EMBO, Therapy, Cell, Walter, LRP2, BIAF, Biology, Breast, Medical imaging, Research, D.C

Dr. Elzis recent research that will be presented next week at Cell Bio looks at why it works.

Key Points: 
  • Dr. Elzis recent research that will be presented next week at Cell Bio looks at why it works.
  • bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment.
  • OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells.
  • Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio.

TIANGEN to Roll out a Stunning Automated Solution at Cell Bio 2022

Retrieved on: 
Wednesday, November 30, 2022
European Molecular Biology Organization, Thomas D. Pollard, Head, DC, ASCB, Cell biology, LTD, S16, Society, GM, Booth, EMBO, Research, Cell, Fine chemical, A4

It could be a stunning product for most molecular biologists and cell biologists to learn about.

Key Points: 
  • It could be a stunning product for most molecular biologists and cell biologists to learn about.
  • "Researchers spend lots of their time on the repetitive hands-on experiment, while there hasn't been an optimal automated nucleic acid extraction solution in the global life science market.
  • said Kefei Sun, the GM of TIANGEN, "TIANGEN develops the TGuide S16, that is groundbreaking to this field".
  • It has been committed to providing customers with a total solution from sample storage to nucleic acid extraction and detection.

Lisata Therapeutics’ Director and Scientific Founder of the CendR Platform™ Technology, Erkki Ruoslahti, M.D., Ph.D., Receives 2022 Albert Lasker Basic Medical Research Award

Retrieved on: 
Thursday, September 29, 2022
American Academy, Lasker Award, Safety, Canada Gairdner International Award, Center, City of Hope National Medical Center, Biology, Patient, Perseverance, Nasdaq, Sanford Burnham Prebys Medical Discovery Institute, Research, Disease, University of California, Santa Barbara, National Academy of Medicine, Life, DRS, CD34, Japan Prize, University of Helsinki, Tumor microenvironment, University of Turku, RGD, National Academy of Inventors, Integrin, California Institute for Quantitative Biosciences, Director, European, Neoplasm, Physiology, City, European Molecular Biology Organization, Board of directors, Tissue, GLOBE, Peptide, Health, Therapy, Thrombosis, National academy, CendR, Japan, Pancreatic cancer, Cell adhesion, Nanomedicine, Survival, Cancer, Cell, Medical research, RNA, Heart, University, Pharmaceutical industry, Technology, Science

The Albert Lasker Basic Medical Research Award is one of the highly competitive and distinguished international prizes for medical science awarded by the Lasker Foundation.

Key Points: 
  • The Albert Lasker Basic Medical Research Award is one of the highly competitive and distinguished international prizes for medical science awarded by the Lasker Foundation.
  • Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics.
  • Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively.
  • In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform.

Lupus Research Alliance Awards 2022 Lupus Insight Prize to Immunologist Dr. Akiko Iwasaki

Retrieved on: 
Thursday, June 23, 2022
LIP, Journal, Map, Howard Hughes Medical Institute, Neutrophil, African Americans, Developmental Biology (journal), National academy, European, Disease, MD, NETS, Native, Board of directors, Lupus, Yale school, Autoantibody, American Academy, Skin, Heart, European Molecular Biology Organization, Infection, Neurodegeneration, Inflammation, Tissue, Association, Oklahoma Medical Research Foundation, Federation, Brain, Conditional sentence, Immune system, LRA, SLE, Sterling, Board, Biomedical Research, Doctor of Philosophy, End organ damage, Virus, Joint, Yale School of Medicine, Patient, Multimedia, COVID, Blood, Woman, Risk, Antibody, National Academy of Medicine, Gene, Arthritis, National, Cancer, Research, Medical research, Genome, SAN, Pharmaceutical industry, Vaccine, Dermatology, Epidemiology

SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) awarded its 2022 Lupus Insight Prize (LIP) to Akiko Iwasaki, PhD, for her discovery of the link between endogenous retroviruses and systemic lupus erythematosus (SLE). The award was presented to Dr. Iwasaki at the 22nd Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2022) by Judith James, MD, PhD, LRA Scientific Advisory Board member and Lou Kerr Chair in Biomedical Research and Chair of the Arthritis and Clinical Immunology Program at the Oklahoma Medical Research Foundation. The $100,000 award recognizes and honors an outstanding investigator who has, within the past five years, published a novel and important research insight into lupus that advances our understanding of this disease and could open new avenues for lupus diagnosis and treatment.

Key Points: 
  • SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) awarded its 2022 Lupus Insight Prize (LIP) to Akiko Iwasaki, PhD, for her discovery of the link between endogenous retroviruses and systemic lupus erythematosus (SLE).
  • "I am honored to receive this prestigious award, and I sincerely thank the Lupus Research Alliance for recognizing our research.
  • The Lupus Research Alliance, the largest nongovernmental, nonprofit research organization dedicated to lupus research worldwide, aims to transform treatment while advancing toward a cure by funding the most innovative lupus research in the world.
  • Because the Lupus Research Alliance's Board of Directors funds all administrative and fundraising costs, 100 percent of all donations goes to support lupus research programs.